Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Pefloxacin
A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.
Year introduced: 1989
Cytochrome P-450 CYP1A2 Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2.
Year introduced: 2015
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.
Year introduced: 2011
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA.
Year introduced: 2004(1963)
Fluoroquinolones
A group of QUINOLONES with at least one fluorine atom and a piperazinyl group.
Year introduced: 2002
Quinolones
A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.
Year introduced: 1994
Quinolines
Heterocyclic Compounds, 2-Ring
A class of heterocyclic compounds that include a two-ring fused structure. Both aromatic and non-aromatic ring structures are included in this category.
Year introduced: 1998
Heterocyclic Compounds
Cyclic compounds that include atoms other than carbon in their ring structure.
Heterocyclic Compounds, Fused-Ring
Multiple ring heterocyclic compounds containing two or more rings that share two atoms and one bond in common.
Year introduced: 2017
Cytochrome P-450 Enzyme Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 ENZYMES.
Metabolic Side Effects of Drugs and Substances
Specific effects of drugs and substances on metabolic pathways such as those occurring through the CYTOCHROME P-450 ENZYME SYSTEM. These include effects that often result in DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; and HERB-DRUG INTERACTIONS.
Topoisomerase Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASES.
Therapeutic Uses
Uses of chemicals which affect the course of conditions, diseases, syndromes or pathology to benefit the health of an individual.
Year introduced: 2004
Molecular Mechanisms of Pharmacological Action
Pharmacological activities at the molecular level of DRUGS and other exogenous compounds that are used to treat DISEASES and affect normal BIOCHEMISTRY.
Year introduced: 2008(2004)
Pharmacologic Actions
A broad category of chemical actions and uses that result in the prevention, treatment, cure or diagnosis of disease. Included here are drugs and chemicals that act by altering normal body functions, such as the REPRODUCTIVE CONTROL AGENTS and ANESTHETICS. Effects of chemicals on the environment are also included.
Year introduced: 2004(1999)
Chemical Actions and Uses
A group of pharmacologic activities, effects on living systems and the environment, and modes of employment of drugs and chemicals. They are broken into actions, which describe their effects, and uses, which describe how they are employed.
Year introduced: 1999
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
Year introduced: 1975(1964)
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Anti-Infective Agents
Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection.